# Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

> **NCT04953897** · PHASE1 · RECRUITING · sponsor: **Taiho Oncology, Inc.** · enrollment: 18 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** ASTX727

## Key facts

- **NCT ID:** NCT04953897
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-15
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04953897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04953897, "Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04953897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*